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Abstract
Momordica charantia is a perennial plant with reported health benefits.
Food-derived molecules, like the novel peptide BG-4 found in Momordica charantia,
have been shown to have anticancer properties by promoting apoptosis in colon
cancer cells. Ovarian cancer (OVCA) is the deadliest form of all gynecological
cancers. The high fatality rate of OVCA is due to late presentation of the disease,
cancer persistence, and recurrence in patients. The objective of this study was to
determine the ability of BG-4 to cause cytotoxicity to ovarian cancer cells
(A27801AP and COV318) and determine the mechanism involved by measuring
proteins associated with apoptosis. BG-4 treatment caused a decrease in viable cell
count by 65.1% at 250 μg/mL (A27801AP) and 19.8% at 250 μg/mL (COV318). The
mechanism involved in the decrease in viable cell count is due to promoted
apoptosis as evidenced by increased percentage of A27801AP undergoing apoptosis
from 7.1% (untreated) to 23.9% (BG-4 treated, 250 μg/mL). The molecular
mechanism explanation for the induced apoptosis of ovarian cancer cells due to BG4 is caused by the increase in expression of pro-apoptotic marker BAX while
reducing expression of anti-apoptotic marker XIAP. This led to an increase in
expression of capsase-3 and caused an affect on the expression of cell cycle proteins
p21 and CDK2. These findings support the hypothesis that there is anti-cancer
potential for the BG-4 peptide isolated from Momordica charantia in vitro against

ovarian cancer and should be further addressed using in vivo models of ovarian
carcinogenesis.

1. Introduction
Ovarian cancer (OVCA) is estimated to account for 14,170 new deaths in
2018, making it the most deadly form of gynecological cancer (Siegel et al, 2016). In
2012, GLOBOCAN reported that OVCA accounted for 239,000 new cases worldwide
and 152,000 deaths worldwide. As a result, OVCA is the 7th most common cancer
and 8th most common cause of death in women worldwide (Ferlay et al, 2015).
OVCA incidence rates are higher in more developed regions causing it to be the 5th
most common cause of death in women in the United States (Siegel et al, 2016)).
Breast cancer is ten times more common in American women than OVCA, but
OVCA is more deadly (Committee on the State of the Science in Ovarian Cancer
Research et al, 2016). The death-to-incidence ratio for OVCA is more than three
times higher than for breast cancer (Committee on the State of the Science in
Ovarian Cancer Research et al, 2016). In 2011, the 5-year survival rate for OVCA was
45.6% (Committee on the State of the Science in Ovarian Cancer Research et al,
2016). The 5-year survival rate for breast cancer, endometrial cancer, and cervical
cancer was 90%, 80% and 70% respectively (Committee on the State of the Science
in Ovarian Cancer Research et al, 2016).
Women have a 1 in 71 chance to become diagnosed with OVCA during their
lifetime and a 1 in 95 chance to die from the disease (Razi et al, 2016). The high rate
is correlated to the absence of screening which leads to diagnosis of disease at

advanced stages (Razi et al, 2016). The high fatality rate of OVCA is due to late
presentation of disease, cancer persistence, and chemotherapy resistance (Thibault
et al, 2014). Most often, the treatment for OVCA is chemotherapy, which causes
severe side effects including gastrointestinal toxicity, febrile neutropenia and
peripheral neuropathy and other non-hematological toxicities (Dia & Pangloli,
2016).
Cancer cells grow through the avoidance of apoptosis, or programmed cell
death (Hanahan et al, 2011). Apoptosis is controlled by various protein machineries,
including proteins involved in intrinsic mitochondrial pathways and extrinsic death
receptor-mediated pathways (Dia & Krishnan, 2016). A key approach to combatting
cancer cell growth is the activation of the apoptosis pathway (Dia & Krishnan,
2016).
Momordica charantia, commonly known as the bitter melon or bitter gourd
(BG), comes from the family Cucurbitacae (Dandawate et al, 2016). This plant is
commonly cultivated in Asia, the Amazon, east Africa, and the Caribbean
(Dandawate et al, 2016). BG is commonly used as folk medicine to treat malaria,
peptic ulcers, kidney stones, and eczema (Dandawate et al, 2016). BG is also
reported to have anti-oxidant, anti-inflammatory, anti-cancer, anti-diabetic, antibacterial, anti-obesity, and immunomodulatory activities (Dandawate et al, 2016).
Different portions of the BG plant possess anticancer properties (Dia &
Krishnan, 2016) and previous studies have shown these anticancer properties.
MAP30, an anti-HIV protein, has been shown to inhibit MDA-MB-231 breast cancer
cells and has led to increased survival in mice with MDA-MB-231 tumors (Lee-

Huang et al, 2000). Methanolic extract of BG has been shown to lead to reduced
proliferation and autophagy of colorectal cancer (Kwatra et al, 2013). BG lectin has
been shown to induce G2/M cell cycle arrest, autophagy, and apoptosis in
hepatocellular cancer (Zhang et al, 2015). BG-4 has been shown to inhibit
proliferation of colon cancer cells by promoting apoptosis through down-regulation
of anti-apoptotic proteins (Bcl-2 and XIAP), up-regulation of pro-apoptotic proteins
(BAX and capsase-3), and modification of cell cycle proteins (p21 and CDK2) (Dia &
Krishnan, 2016). These previous studies on the beneficial roles of the BG plant on
various forms of cancer and the previous study indicating that BG-4 inhibits growth
of colon cancer due to the promotion of the apoptosis pathway serve as scientific
premise to study the ability of BG-4 to cause cytotoxicity to ovarian cancer cells via
promotion of the apoptotic pathway.

2. Methods and Materials
Cell lines and cell culture
A27801AP was a kind gift from Dr. Tito Fojo (National Cancer Institute, NIH),
and COV318 was from Dr. Gabor Tigyi (University of Tennessee Health Science
Center, Memphis TN). The cells were grown in RPMI 1640 growth medium
supplemented with 10% heat inactivated fetal bovine serum, 1% penicillinstreptomycin and 1% sodium pyruvate. The cells were grown in a humidified incubator
with 5% CO2 at 37°C.

Cell proliferation Assay
Approximately twenty thousand ovarian cancer cells from the cell lines
A27801AP and COV318 were grown in RPMI 1640 medium containing 10% fetal bovine
serum, 1% penicillin-streptomycin and 1% sodium pyruvate. The cells were then plated
in a 96-well plate in 200 μL volume and allowed to attach overnight in humidified 5%
CO2 incubator at 37 °C. Cells were treated with BG-4 extract ranging from 0 to 1000
μg/ml for 24-hours. After treatment, medium was removed and 20 μL of 3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt, (MTS, Promega, Madison, WI, USA)-phenazine methosulfate (PMS, Acros
Organics) solution followed by 100 μL of growth medium were added. The plate was
incubated at 37°C for 2 hours and absorbance was read at 490 nm. Proliferation was
expressed as percentage of untreated control cells. The experiment was performed at time
24-hour with two independent trials and 4 replicates per trial.

Western Blotting
OVCA cells (cell line A27801AP only) were seeded in a 6-well plate at a density
of 5 x 105 cells /mL, allowed to attach overnight, treated with BG-4 for 24-hour and lysed
with RIPA buffer. Cell lysates were vortexed for 5 minutes and centrifuged at 14,000 x g
for 10 minutes at 4 °C. The supernatant was collected, mixed with Laemmli buffer
containing 5% β-mercaptoethanol, boiled for 5 minutes and stored at -20 °C until
analysis was performed. A portion of the supernatant was used for protein content
determination using Bradford assay. The whole cell lysates used for Bax, Bcl-2, XIAP,

caspase-3, p21 and CDK2 (Proteintech Group, Inc. Rosemont IL) and GAPDH (Santa
Cruz Biotechnology, Santa Cruz, CA) expressions. Western blot analysis was conducted
by loading whole cell lysates (25 μg protein) in 4-20% Tris-HCl gel (Bio-Rad
Laboratories), and then run at 200 V for 35 minutes at room temperature. Once complete,
the gels were transferred to a PVDF membrane (GE Healthcare Life Sciences, Pittsburg,
PA) at 110 V for 1 hour at 4 °C. The blots produced were blocked with 5% non-fat dry
milk for 1 hour at room temperature, then washed 3 times with TBS containing 0.1%
Tween 20 (TBST) for 5 minutes and incubated with primary antibody overnight at 4 °C
at 1:1000 dilution. The blots were washed with TBST 3 times for 10 minutes and
incubated with anti-rabbit or anti-mouse secondary antibody at 1:5000 dilution for 2
hours at room temperature. After washing with TBST, the blots were imaged with CDigit Blot scanner (Li-Cor Biosciences, Lincoln, NE) using WesternSure ECL Substrate
(Li-Cor Biosciences, Lincoln, NE). The intensity of the bands was quantified using
Image Studio Software (Li-Cor Biosciences, Lincoln, NE). Each experiment was
performed in two independent replicates.

Apoptosis Assay
A27801AP cells were seeded at 5x105 cells/mL in a 6-well plate and allowed to
attach overnight in humidified 5% CO2 incubator at 37 °C. Then, cells were treated with
0, 125, and 250 μg/mL BG-4 for 16 hours. Following treatment, growth medium was
removed and cells were washed with ice-cold PBS twice and detached from the well
plate. Cell suspension was centrifuged at 500 x g for 5 minutes at 4 °C and re-suspended
in Annexin V binding buffer. Cell suspension (100 μL) was stained with 10 μL Annexin

V-FITC (Biotium, Inc., Hayward, CA) and 10 μL propidium iodine (Biotium, Inc.,
Hayward, CA) for 15 minutes in the dark at room temperature. After staining, 400 μL of
binding buffer was added to the suspension and analyzed using BD Accuri C6 flow
cytometer (BD Biosciences, San Jose, CA). A total of 20,000 events were acquired and
analyzed using BD Accuri C6 software package.

Statistical Analysis
Data analysis was done using Proc GLM of SAS Software version 9.4 and
significance was reported at P < 0.05 with post-hoc Turkey test for separation of means
as indicated by different letters. For expression of protein markers related to apoptosis
and cell cycle, each concentration of BG-4 treatment was compared against the untreated
sample. Mean values represented as bars with different letter(s) are statistically
different from each other (P < 0.05, n=2).

3. Results
BG-4 caused cytotoxicity to ovarian cancer cells. As shown in Fig. 1, BG-4
dose-dependently led to proliferation inhibition in OVCA cells in vitro for COV318 ad
1AP-OVCA cell lines. At 0 μg/mL, both cell lines are labeled with 100% viable cells.
At 250 μg/mL, COV318 proliferation significantly decreased by 19.8% after 24 hour
treatment while 1AP significantly decreased by 65.1%.
BG-4 promoted modified expression of proteins associated with
apoptosis and cell cycle. As shown in Fig. 2, protein expression associated with
apoptosis and cell cycle was measured. In Fig. 2A, BG-4 at 250 μg/mL significantly

modified the expression of different apoptotic markers in OVCA-1AP cells by
increasing the expression of apoptosis executioner protein caspase-3 and proapoptotic protein Bax by 2.2-fold and 2.8-fold, respectively and decreasing the
protein expression of anti-apoptotic protein XIAP by 0.8-fold. Anti-apoptotic protein
Bcl-2 experienced no change in protein expression when treated with BG-4. In an
effort to further understand the anti-proliferative effect of BG-4 on OVCA cells, the
expression of protein markers associated with cell survival, particularly cell cycle
proteins, was measured. As shown in Fig. 2B, BG-4 at 250 μg/mL significantly
modified the expression of cyclin dependent kinase inhibitor p21 by 3.6-fold but
reduced the expression of CDK2 by 0.6-fold.
BG-4 promoted apoptosis in 1AP OVCA cells. 1AP OVCA cells were treated
with 0, 125, 250 μg/mL for 16 hours. The 16-hour time point was chosen based on
previous proliferation studies. In these studies, 24-hour BG-4 treatment led to
significant cytotoxic effects. The 16-hour time point allowed us to detect cells
undergoing early apoptosis. As shown in Fig. 3A, there was a dose-dependent BG-4
treatment increase in the number of cells undergoing apoptosis (quadrant 2 in flow
cytometry figures). As shown in Fig. 3B, the percentage of 1AP OVCA live cells went
from 90.0% (untreated) to 73.9% and 68.8% for 125 μg/mL and 250 μg/mL
treatment, respectively. Early apoptotic cells went from 7.1% (untreated) to 21.0%
and 24.0% for 125 μg/mL and 250 μg/mL treatment, respectively. Late apoptotic
cells went from 2.0% (untreated) to 3.7% and 5.4% for 125 μg/mL and 250 μg/mL
treatment, respectively. Necrotic cells were from 1.0% (untreated) to 1.4% and
1.8% for 125 μg/mL and 250 μg/mL treatment, respectively.

4. Discussion
We report that BG-4 has the ability to induce cytotoxicity in ovarian cancer
cells. BG-4 dose-dependently inhibited ovarian cancer cell growth as shown in Fig. 1.
This inhibition of growth caused by BG-4 could be attributed to its capability to
inhibit trypsin activity. Previous studies have shown that trypsin inhibitors from
food sources, like the Kunitz trypsin inhibitor from soybean, possess anticancer
properties (Dia & Krishnan, 2016). Previous studies have also shown that ethanolic
protein extracts of BG-4 from Momordica charantia seed inhibited trypsin activity
higher than purified soybean Kunitz trypsin inhibitor (Dia & Krishnan, 2016). As a
result, these previous studies support our findings that BG-4 possesses anti-cancer
properties, which could be attributed to its capability to inhibit trypsin, and may be
used as either chemotherapeutic or chemopreventative against OVCA.
Next, we investigated the mechanism through which BG-4 caused a cytotoxic
effect on OVCA-1AP ovarian cancer cells. As shown in Fig.2A and Fig. 2B, the
potential mechanism of cytoxicity involves the induction of the apoptosis pathway.
Apoptosis, or programmed cell death, consists of removal of damaged and mutated
cells. Therefore, dysregulation of the apoptosis pathway can lead to an increase in
the growth of ovarian cancer cells. Ovarian cancer cells grow through the avoidance
of apoptosis by developing mechanisms to survive (Hanahan et al, 2011). Therefore,
the induction of apoptosis through treatment of BG-4 in ovarian cancer cells is a
good strategy to combat malignancy. BG-4 at 250 μg/mL significantly modified the
expression of different apoptotic markers in OVCA-1AP cells as measured by flow

cytometry. As shown in Fig. 3A, there was a dose-dependent BG-4 treatment
increase in the number of cells undergoing apoptosis.
The treatment of BG-4 for OVCA-1AP cells activated the apoptosis pathway
by modifying the expression of proteins associated with apoptosis and the cell cycle.
At 250 μg/mL, BG-4 led to a significant increase in the expression of active caspase3. The increase in caspase-3 could be responsible for the increase in apoptotic cells
observed in flow cytometry experiments (Fig. 3a). Caspase-3 is an executioner
protein that is responsible for executing apoptotic events, but can be inhibited by
XIAP. At 250 μg/mL BG-4 treatment, XIAP expression was reduced significantly thus
leading to an increase in expression of Caspase-3.
At 250 μg/mL, BG-4 led to a significant increase in the expression of proapoptotic Bax. Bax is a member of the Bcl-2 family and the activation of Bax can lead
to mitochondrial outer membrane permeabilitization leading to the release of proapoptotic factors (Dia & Krishnan, 2016).Increased Bax expression in clinics is
associated with increased cancer survival (Dia & Krishnan, 2016). Therefore, the
increased expression of Bax due to BG-4 treatment indicated potential use of BG-4
as an anti-ovarian cancer therapy.
The capability of ovarian cancer cells to multiply and proliferate is an
important aspect of cancer cell survival that is affected by different cell cycle
proteins. CDK2 is a cyclin dependent kinase that regulates the cell cycle from G1 to
S-phase. Therefore, CDK2 is important in cell proliferation and is overexpressed in
ovarian cancer cells. A cyclin dependent kinase inhibitor, p21, is a regulator of
tumor suppressor pathways and is important in combating ovarian cancer. The

results indicate that BG-4 treatment at 250 μg/mL increased the expression of the
antitumor p21 and led to the reduction in expression of CDK2 in OVCA-1AP ovarian
cancer cells. Therefore, we conclude that BG-4 is capable of inducing apoptosis in
ovarian cancer cells by affecting the expression of proteins involved in cell survival
and proliferation.
In summary, we report that BG-4 from Momordica charantia possesses
anticancer properties. In addition, this study reports that BG-4 has the capability of
activating apoptosis in human ovarian cancer cells. Therefore, these findings
support the idea for potential use of BG-4 as an ovarian cancer therapeutic agent
and should be further studied using in vivo models of ovarian carcinogenesis.
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BG-4 affects the viability of COV318 ovarian
cancer cells
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Figure 1A: BG-4 purified from Momordica chrantia caused dose-dependent
cytotoxicity in COV318 OVCA cells. BG-4 treatment led to a decrease in viable cell
count by 19.8% at 250 μg/mL. Mean values represented as bars with different
letter(s) are statistically different from each other (P < 0.05, n=2).

BG-4 affects cell viability of 1AP ovarian cancer
cells
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Figure 1B: BG-4 purified from Momordica chrantia caused dose-dependent
cytotoxicity in 1AP (A27801AP) OVCA cells. BG-4 treatment led to a decrease in
viable cell count by 65.1% at 250 μg/mL. Mean values represented as bars with
different letter(s) are statistically different from each other (P < 0.05, n=2).

A.) 1AP caspase-3, BAX, Bcl-2, and XIAP (apoptotic markers)

B.) 1AP p21 and CDK2 (cell cycle markers)

Figure 2: BG-4 mechanism of action in inducing apoptosis in OVCA cells (1AP
cell line). (A) In 1AP-OVCA cells, BG-4 promoted apoptosis by increasing caspase-3
and BAX leading to a reduced expression of XIAP and no change in expression of Bcl2. (B) In 1AP-OVCA cells, BG-4 increased the expression of p21 leading to a
reduction in expression of CDK2. All analyses were done in at least two independent
replicates. Mean values represented as bars with different letter(s) are statistically
different from each other (P < 0.05, n=2).
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Figure 3: BG-4 induces apoptosis in OVCA 1AP cells as measured by flow
cytommetry. (A) Treatment of cells with BG-4 led to an increased percentage of
OVCA cells undergoing apoptosis. (B) Quantification of OVCA cells undergoing
apoptosis as a result of BG-4 treatment. The live cells were from 90.0% (untreated)
to 73.9% and 68.8% for 125 μg/mL and 250 μg/mL treatment, respectively. Early
apoptotic cells were from 7.1% (untreated) to 21.0% and 24.0% for 125 μg/mL and
250 μg/mL treatment, respectively. Late apoptotic cells were from 2.0% (untreated)
to 3.7% and 5.4% for 125 μg/mL and 250 μg/mL treatment, respectively. Necrotic

cells were from 1.0% (untreated) to 1.4% and 1.8% for 125 μg/mL and 250 μg/mL
treatment, respectively. Mean values represented as bars with different letter(s) are
statistically different from each other (P < 0. 05, n=2).

